V. N. Gorodin

V. N. Gorodin

Auto-generated profile, based on publicly available information

V. N. Gorodin

Kuban State Medical University

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2021 in Infekcionnye bolezni
Verified
Journal Article
Closed access
Vladimir ChulanovVladimir Chulanov
Vladimir Chulanov
VGV.N. Gorodin
V.N. Gorodin
OSO.I. Sagalova
O.I. Sagalova
MIM.R. Ivanova
M.R. Ivanova
NDNalchik Center For The Prevention And Control Of Aids And Infectious Diseases
Nalchik Center For The Prevention And Control Of Aids And Infectious Diseases
ISI.V. Shestakova
I.V. Shestakova
Objective. To model the current and future impact of the chronic hepatitis C disease burden if the current treatment paradigm continues and is effective and if WHO strategy is implemented successfully. Materials and methods. A dynamic disease progression model was constructed in Microsoft Excel (Microsoft Corp., USA) in collaboration with CDA (Center for Disease Analysis, USA) similar to that used in previous studies. As no accurate data on HCV prevalence in Russia and its federal subjects is available, calculations were based on the prevalence of 2.5% and 4.1%. Results. The modelling suggests that, unless the treatment paradigm is changed, the chronic hepatitis C prevalence will remain the same, whereas the mortality and the rate of other HCV-related outcomes (HCC, decompensated cirrhosis) will more than double by 2030. Achieving WHO global strategy targets in Russia will help reduce the total number of infected individuals by 90% and the number of liver-related deaths by 65% saving >45,000 or >77,000 lives under the scenarios with 2.5% and 4.1% prevalence respectively. However, such trends will only take place if WHO strategy is implemented successfully. Conclusion. Regardless of the epidemiologic input data, elimination of HCV infection in Russia appears feasible; however, it requires financial support from the government and a range of organizational measures. Key words: HCV infection, chronic HCV infection, WHO strategy, antiviral therapy

1 January 2021 in Infekcionnye bolezni
Verified
Journal Article
Closed access
VGV.N. Gorodin
V.N. Gorodin
DMD.L. Moisova
D.L. Moisova
SZS.V. Zotov
S.V. Zotov
AVA.A. Vanyukov
A.A. Vanyukov
YСYu.E. Сhumakova
Yu.E. Сhumakova
KHKrasnodar Specialized Clinical Infectious Diseases Hospital
Krasnodar Specialized Clinical Infectious Diseases Hospital
Objective. To analyze the efficacy of levilimab in patients with COVID-19 to optimize proactive anti-inflammatory therapy. Patients and methods. This single-center retrospective observational controlled study included 75 COVID-19 patients with a mean age of 58.6 years who received intravenous (71%) or subcutaneous (29%) levilimab at a dose of 324 mg on day 9 of the disease [range: 7.0–12.0 days]. Ten patients (14%) additionally received tocilizumab, whereas 14 participants (19%) received only levilimab without dexamethasone. The control group (received no levilimab) included 29 matched patients. The levels of C-reactive protein (CRP), ferritin, fibrinogen, creatine phosphokinase (CPK), D-dimer, as well as lymphocyte and white blood отсутcell (WBC) counts were measured daily. The percentage of lung damage was assessed using computed tomography (CT) at baseline and later in dynamics. The primary endpoint was patient's transfer to the intensive care unit (ICU). Statistical analysis was performed using the Statistica v. 12 software (StatSoft, USA); the risk of transfer to ICU was evaluated using the Kaplan-Meier cumulative proportional risk method and Cox proportional hazards model by calculating relative risks with a 95% confidence interval (RR [CI]). The dynamics of patients' status and its association with the route of levilimab administration was evaluated using a seven-point scale (seven-category scale) approved by the World Health Organization. Results. No lethal outcomes were registered in this study. Levilimab reduced the risk of transfer to the ICU; significant covariates included obesity (RR = 11.09 [1.29–95.72]) and percentage of lung damage on CT scans (RR = 1.06 [1.01–1.13]). The target group for levilimab therapy should include patients with moderate COVID-19 before day 10 of the disease, who have not yet received corticosteroids (CSs), with a maximum body temperature of ≤38.5°C, lung damage <40% on CT at the time of therapy initiation, and CPK <300 U/L. Levilimab therapy is more beneficial for patients with diabetes mellitus, obesity, severe arterial hypertension, and stomach and duodenal ulcers. Intravenous administration of levilimab at a dose of 324 mg is optimal for a reliable prevention of excessive cytokine release. Levilimab demonstrated equivalent positive effects both together with CSs, and when used alone. Levilimab without CSs alleviated hyperglycemia and normalized WBC count. The following laboratory parameters were found to be most important for the decision on levilimab initiation and further control of treatment efficacy: absolute lymphocyte count, CRP, fibrinogen, and CPK. Levels of lactate dehydrogenase, ferritin, platelets, D-dimer did not provide any reliable information on the mitigation of systemic inflammation. Key words: interleukin-6 receptor blockers, levilimab, COVID-19 treatment

1 January 2022 in Infekcionnye bolezni
Verified
Journal Article
Closed access
INI.V. Nesterova
I.V. Nesterova
VGV.N. Gorodin
V.N. Gorodin
GCG.A.Chudilova Chudilova
G.A.Chudilova Chudilova
VCV.N. Chapurina
V.N. Chapurina
VMV.A. Matushkina
V.A. Matushkina
ТSТ.а. Semenenko
Т.а. Semenenko
Investigation of molecular mechanisms associated with interferon (IFN) production and receptor function of neutrophil granulocytes (NGs) in COVID-19 is highly relevant because it can be promising in the search for new therapeutic strategies targeting NGs and their reactivity to restore and strengthen the innate immune response against SARS-CoV-2. Objective. To assess the effects of recombinant IFN-α2b on the phenotype of CD16+IFNα/βR1–CD119+, CD16+IFNα/βR1+CD119–, and CD16+IFNα/βR1+CD119+ NGs from peripheral blood of patients with COVID-19 in an in vitro experiment. Patients and methods. We analyzed blood samples from 31 patients with a mean age of 61 years (range: 57;71 years) with moderate COVID-19. We assessed the number of CD16+IFNα/βR1–CD119+, CD16+IFNα/βR1+CD119–, and CD16+IFNα/βR1+CD119+ NGs, receptor density (FC 500, ‘Beckman Coulter,’ USA), phagocytic activity of NGs before and after incubation with recombinant IFN-α2b. We also measured serum levels of several cytokines, including IFNα, IFNγ, IL-6, IL-8 (ELISA, ‘Vektor-Best’ LLC). The control group comprised 22 adult healthy individuals with a mean age of 58 years (range: 57; 70 years). Results. Patients with moderate COVID-19 demonstrated low serum levels of IFNα and IFNγ along with elevated levels of IL-6 and IL-8. We observed transformation of 3 phenotypes among NG subpopulations: CD16+IFNα/βR1–CD119+, CD16+IFNα/βR1+CD119-, and CD16+IFNα/βR1+CD119+. We observed positive remodulating effects of recombinant IFN-α2b on the number and phenotype of NG subpopulations and their phagocytic activity in our in vitro experiment. Conclusion. Recombinant IFN-α2b demonstrated positive effects in in vitro experiments; therefore, it can be considered in the future as a potential therapeutic tool for moderate COVID-19. Restoration of type I IFN might be an effective treatment option for COVID-19, because it can promote faster virus elimination, restore normal functioning of the IFN system, and have positive regulatory effects on the phenotype of NG subpopulations. Key words: neutrophil granulocytes, subpopulations, COVID-19, phenotype, recombinant interferon α2b

1 January 2021 in Infekcionnye bolezni
Verified
Journal Article
Closed access
VGV.N. Gorodin
V.N. Gorodin
DMD.L. Moysova
D.L. Moysova
SZS.V. Zotov
S.V. Zotov
KDKrasnodar Specialized Clinical Hospital For Infectious Diseases
Krasnodar Specialized Clinical Hospital For Infectious Diseases
AVA.A. Vanyukov
A.A. Vanyukov
YTYu.V. Tikhonenko
Yu.V. Tikhonenko
Objective. To analyze polymorphisms of genes involved in hemostasis among patients with coronavirus disease 2019 (COVID 19) to improve the diagnosis of coagulopathy and prognosis of COVID-19 severity. Patients and methods. We have examined 52 patients with COVID-19 aged 33 to 84 years. Of them, 30 individuals (Group 1) were hospitalized with extremely severe (1A) and severe (1B) disease, whereas 22 patients with mild and asymptomatic disease were treated in outpatient departments (group 2). We assessed allelic variants of genes associated with hemostasis dysfunction (including FGB, FII, FV, FVII, F13A1, PAI-I, Gp1a, and Gp3a) using genomic DNA isolated from peripheral blood leukocytes. Polymorphisms were detected by polymerase chain reaction. Data analysis was performed using the Statistica, version 12 (StatSoft, USA). To compare independent categorical variables, we constructed contingency tables, performed Pearson chisquare test with Yates correction, Fisher exact test, and calculated relative risk (RR) [CI]. Results. COVID-induced coagulopathy (CAC) was diagnosed in 16.7% of patients; risk of CAC was identified in 30% of patients; sepsis-induced coagulopathy (SIC) was observed in 3.3% of patients; none of study participants had disseminated intravascular coagulation (DIC). Hemostasis impairments were more common in group 1A (RR = 2.28 [1.16–4.48]). Only patients from Group 1 had mutations in the gene encoding prothrombin (FII) –6.9% (RR = 1.78 [1.40–2.28]); protective polymorphisms in the FVII gene were more common in patients from Group 2 (χ2 = 3.28, р = 0.046); the rs 5985 polymorphism in the F13A1 gene was more common in patients from Group 1 (RR = 1.73 [1.06–2.82]). Patients with extremely severe COVID- 19 were more likely to have polymorphisms in the Gp1a gene (ITGA2) (RR =1.64 [1.05–2.56]) and F13A1 gene (χ2 = 2.67, р = 0.05), as well as homozygous mutation in the FII gene; they had no polymorphisms in the FVII gene (10976G→A). Thrombophilia, detected in 3 patients from Group 1, was a risk factor for thrombocytopenia (RR = 13.5 [3.56–51.23]), САС (RR = 9.0 [3.1–26.16]), and death (n = 4). The 4G allele (4G/4G, 4G/5G variants) in the PAI-I gene (rs 1799889), causing impaired fibrinolysis, was more frequently registered in patients with mild COVID-19 (91%) than in those with extremely severe COVID-19 (70%). It is possible that patients with extremely severe disease develop transient hyperfibrinolysis, which results in the transformation of local pulmonary COVID-19 into sepsis. Therefore, the 4G/4G and 4G/5G polymorphisms may have a protective role. Key words: hemostasis, COVID-19, polymorphism, genetics, COVID-induced coagulopathy

28 July 2025 in Epidemiology and Vaccinal Prevention
Verified
Journal Article
Open access
PDF file
EPE. N. Ponomareva
E. N. Ponomareva
RPRoman Polibin 
Roman Polibin 
NPN. D. Pakskina
N. D. Pakskina
VGV. N. Gorodin
V. N. Gorodin
EME. Yu. Malinnikova
E. Yu. Malinnikova
Relevance. The study of additional organization of vaccination in the regions of the country is an important task, especially in the context of global challenges associated with infectious diseases.Aim. To analyze the existing regional calendars of preventive vaccinations in the subjects of the Russian Federation.Result. A number of Russian regions provide additional vaccination as part of regional preventive vaccination calendars. Some regions create additional programs or comprehensive plans to organize immunoprophylaxis.Conclusion. Regional calendars of preventive vaccinations allow to adapt vaccination programs to modern conditions and can be considered as a tool oftransitional period of implementation of the strategy of development of immunoprophylaxis of infectious diseases for the period up to 2035, approved by the order of the Government of the Russian Federation from 29.03.2021 № 774-r in part by including additional vaccinations against vaccine-preventable infections, taking into account the epidemic situation and the presence of high-risk groups of infection in the region.

21 September 2023 in Epidemiology and Vaccinal Prevention
Verified
Journal Article
Open access
PDF file
MDM. A. Davydova
M. A. Davydova
GBG. D. Bryukhanova
G. D. Bryukhanova
VGV. N. Gorodin
V. N. Gorodin
Relevance. Health care-associated infections (HAIs) are one of the global problems of modern healthcare with a negative trend in the growth of this pathology throughout the world, which is due to a complex of reasons, among which the resistance of pathogens of hospital infections to antimicrobials is important, as well as gaps in organization of epidemiological surveillance due to a number of objective and subjective factors (complication of technologies and expansion of the practice of invasive medical interventions, turnover and shortage of personnel in medical institutions, etc.).The purpose of the work is to study the experience of organizing measures for the prevention of HCAI from the standpoint of a systematic approach in Russia and in foreign countries that have the best practices in this area. The purpose of the work is to study the experience of organizing measures for the prevention of HCAI from the standpoint of a systematic approach in Russia and in foreign countries that have the best practices in this area.The results are based on the study of the basic principles of the system approach, its tools, functional organization and universalization, the use of a comprehensive analysis in relation to different areas of medical activity and types of medical care, the sequence of development and implementation of new methods in Russian and foreign experience in the implementation of epidemiological surveillance for HCAI. Problems in the field of organization and practical implementation of preventive measures to prevent the occurrence of HCAI have been identified, and urgent tasks for improving the epidemiological safety of medical activity have been identified.Conclusion. Differences were noted in approaches to the prevention of HAIs in Russia and abroad, concerning the resource provision of molecular biological monitoring of HAI pathogens, as well as the features of teamwork, targeted communication in medical teams and in explanatory work, as well as the implementation of training programs for relatives to care for patients with HAI. Measures are proposed to increase the commitment of medical personnel and collectives in general, other employees of medical organizations to epidemiologically safe skills in their professional activities, to develop patient education programs for personal prevention of HCAI.